By Turna Ray

Epigenomics and DxS have exercised certain cross-licensing options written into a pre-existing strategic agreement around the development of DNA methylation-based in vitro diagnostics.

The two companies announced this week that they have "cross-licensed certain technologies enabling both companies to develop and commercialize IVD products based on DNA methylation that utilize DxS' proprietary Scorpions technology."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.